Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsScientists sought to understand how the programmed death ligand 1 inhibitor durvalumab and the immunomodulatory agent pomalidomide regulate immune cell activation and function in patients with relapsed/refractory multiple myeloma.
[Scientific Reports]
6445218 KA66XQD4 items 1 apa 0 default asc 1 165646 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-390df6f27ca61b17bdfe9152d59d6ded%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22KA66XQD4%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Young%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EYoung%2C%20M.%20H.%2C%20Pietz%2C%20G.%2C%20Whalen%2C%20E.%2C%20Copeland%2C%20W.%2C%20Thompson%2C%20E.%2C%20Fox%2C%20B.%20A.%2C%20%26amp%3B%20Newhall%2C%20K.%20J.%20%282021%29.%20Immunomodulation%20by%20durvalumab%20and%20pomalidomide%20in%20patients%20with%20relapsed%5C%2Frefractory%20multiple%20myeloma.%20%3Ci%3EScientific%20Reports%3C%5C%2Fi%3E%2C%20%3Ci%3E11%3C%5C%2Fi%3E%281%29%2C%2016460.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-95902-x%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-95902-x%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3DKA66XQD4%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Immunomodulation%20by%20durvalumab%20and%20pomalidomide%20in%20patients%20with%20relapsed%5C%2Frefractory%20multiple%20myeloma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%20H.%22%2C%22lastName%22%3A%22Young%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Greg%22%2C%22lastName%22%3A%22Pietz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Whalen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wilbert%22%2C%22lastName%22%3A%22Copeland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ethan%22%2C%22lastName%22%3A%22Thompson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%20A.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%20J.%22%2C%22lastName%22%3A%22Newhall%22%7D%5D%2C%22abstractNote%22%3A%22This%20study%20sought%20to%20understand%20how%20the%20programmed%20death%20ligand%201%20%28PD-L1%29%20inhibitor%20durvalumab%20and%20the%20immunomodulatory%20agent%20pomalidomide%20regulate%20immune%20cell%20activation%20and%20function%20in%20patients%20with%20relapsed%5C%2Frefractory%20%28RR%29%20multiple%20myeloma%20%28MM%29.%20Immunologic%20changes%20in%20peripheral%20blood%20and%20bone%20marrow%20of%20patients%20treated%20with%20durvalumab%20as%20monotherapy%20or%20in%20combination%20with%20pomalidomide%20with%5C%2Fwithout%20dexamethasone%20were%20characterized%20by%20assessing%20subsets%20of%20immune%20cells%20and%20gene%20signatures%20to%20understand%20the%20immunomodulatory%20effect%20of%20the%20treatment.%20Soluble%20PD-L1%20levels%20were%20elevated%20at%20screening%20in%20patients%20with%20RRMM%20but%20did%20not%20correlate%20with%20response%20to%20durvalumab%20combination%20therapy.%20Immune%20cell%20subsets%20were%20increased%20in%20peripheral%20blood%20during%20treatment%20with%20durvalumab%20and%20pomalidomide%2C%20and%20combination%20therapy%20induced%20significant%20gene%20expression%20changes%20in%20the%20MM%20tumor%20microenvironment%20versus%20durvalumab%20alone.%20Estimation%20of%20cell%20populations%20based%20on%20RNA%20sequencing%20data%20revealed%20increased%20monocytes%2C%20neutrophils%2C%20and%20natural%20killer%20cells%20with%20the%20combination%20therapy%2C%20but%20not%20with%20durvalumab%20alone.%20Additionally%2C%20multiplex%20immunofluorescence%20of%20bone%20marrow%20demonstrated%20that%20immune%20populations%20were%20different%20in%20responders%20versus%20nonresponders%20to%20durvalumab%20plus%20pomalidomide%20with%20dexamethasone%20therapy.%20Overall%2C%20durvalumab%20effectively%20blocked%20soluble%20PD-L1%3B%20however%2C%20durvalumab%20monotherapy%20was%20not%20associated%20with%20immunologic%20changes%2C%20which%20were%20observed%20with%20combination%20therapy.%22%2C%22date%22%3A%222021-08-12%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-021-95902-x%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41598-021-95902-x%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-08-13T00%3A37%3A59Z%22%7D%7D%5D%7D
Young, M. H., Pietz, G., Whalen, E., Copeland, W., Thompson, E., Fox, B. A., & Newhall, K. J. (2021). Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. Scientific Reports, 11(1), 16460. https://doi.org/10.1038/s41598-021-95902-x Cite
